De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel

Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E. -M; Augustin, D.; Kuemmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Wuerstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H.; Harbeck, N.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel

Author:

Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E. -M; Augustin, D.; Kuemmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Wuerstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H.; Harbeck, N.

Tübinger Autor(en):

Grischke, Eva-Maria

Published in:

Annals of Oncology (2017), Bd. 28, H. 11, S. 2768-2772

Verlagsangabe:

Oxford Univ Press

Language:

English

Full text:

http://dx.doi.org/10.1093/annonc/mdx494

ISSN:

1569-8041